Wall Street brokerages forecast that U.S. Physical Therapy, Inc. (NYSE:USPH) will announce earnings per share (EPS) of $0.57 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for U.S. Physical Therapy’s earnings, with the lowest EPS estimate coming in at $0.55 and the highest estimate coming in at $0.59. U.S. Physical Therapy reported earnings of $0.48 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.8%. The business is scheduled to report its next quarterly earnings results on Thursday, November 1st.

On average, analysts expect that U.S. Physical Therapy will report full-year earnings of $2.51 per share for the current fiscal year, with EPS estimates ranging from $2.49 to $2.55. For the next fiscal year, analysts anticipate that the business will post earnings of $2.73 per share, with EPS estimates ranging from $2.62 to $2.85. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for U.S. Physical Therapy.

U.S. Physical Therapy (NYSE:USPH) last announced its quarterly earnings results on Thursday, August 2nd. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.05. U.S. Physical Therapy had a return on equity of 13.81% and a net margin of 5.03%. The business had revenue of $115.10 million for the quarter, compared to analyst estimates of $111.77 million. During the same quarter in the prior year, the company earned $0.59 earnings per share. The company’s quarterly revenue was up 10.4% on a year-over-year basis.

A number of analysts recently commented on the company. Barrington Research reiterated a “hold” rating on shares of U.S. Physical Therapy in a report on Friday, August 3rd. Jefferies Financial Group reiterated a “hold” rating and set a $105.00 price target on shares of U.S. Physical Therapy in a report on Friday, August 3rd. Zacks Investment Research upgraded U.S. Physical Therapy from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a report on Tuesday, August 7th. Finally, ValuEngine upgraded U.S. Physical Therapy from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 26th. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $108.00.

In other U.S. Physical Therapy news, Director Mark J. Brookner sold 4,375 shares of the firm’s stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $116.82, for a total value of $511,087.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher J. Reading sold 1,232 shares of the firm’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $116.29, for a total value of $143,269.28. The disclosure for this sale can be found here. Insiders have sold 28,929 shares of company stock worth $3,342,700 over the last quarter. 2.50% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. increased its position in U.S. Physical Therapy by 2.8% in the second quarter. Victory Capital Management Inc. now owns 21,790 shares of the company’s stock worth $2,092,000 after buying an additional 590 shares during the last quarter. Citigroup Inc. increased its position in U.S. Physical Therapy by 5.9% in the first quarter. Citigroup Inc. now owns 10,731 shares of the company’s stock worth $873,000 after buying an additional 597 shares during the last quarter. Comerica Bank increased its position in U.S. Physical Therapy by 5.0% in the second quarter. Comerica Bank now owns 13,909 shares of the company’s stock worth $1,413,000 after buying an additional 665 shares during the last quarter. Copeland Capital Management LLC increased its position in U.S. Physical Therapy by 0.4% in the first quarter. Copeland Capital Management LLC now owns 173,261 shares of the company’s stock worth $14,086,000 after buying an additional 693 shares during the last quarter. Finally, BlueMountain Capital Management LLC increased its position in U.S. Physical Therapy by 54.3% in the second quarter. BlueMountain Capital Management LLC now owns 2,691 shares of the company’s stock worth $258,000 after buying an additional 947 shares during the last quarter. 98.14% of the stock is owned by institutional investors and hedge funds.

Shares of USPH stock traded up $0.15 during trading hours on Friday, reaching $126.30. The company had a trading volume of 40,628 shares, compared to its average volume of 58,911. U.S. Physical Therapy has a 12 month low of $57.80 and a 12 month high of $129.65. The company has a quick ratio of 2.06, a current ratio of 2.06 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $1.60 billion, a PE ratio of 60.72, a P/E/G ratio of 4.48 and a beta of 1.14.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 7th. Investors of record on Tuesday, August 14th were issued a dividend of $0.23 per share. The ex-dividend date of this dividend was Monday, August 13th. This represents a $0.92 dividend on an annualized basis and a yield of 0.73%. U.S. Physical Therapy’s dividend payout ratio (DPR) is currently 44.23%.

U.S. Physical Therapy Company Profile

U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.

Read More: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on U.S. Physical Therapy (USPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.